Limitations of Guideline‐Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments
Abstract
Current guidelines recommend FIB‐4 and transient elastography for non‐invasive risk stratification in metabolic dysfunction‐associated steatotic liver disease (MASLD). These tests can predict the presence or absence of advanced fibrosis, but their accuracy for identifying significant fibrosis in MASLD patients eligible for novel drug treatments remains unclear. In a multicenter cohort of 458 biopsy‐proven MASLD patients, we evaluated the suitability of FIB‐4 for identifying MASLD with histologically significant fibrosis (≥ F2). In a subcohort of 291 patients, we further assessed the diagnostic performance of the guideline‐based sequential use of FIB‐4 and transient elastography. We demonstrate that the recommended risk stratification remains suboptimal for the identification of patients with significant fibrosis, resulting in remarkably high false‐positive and false‐negative rates for FIB‐4 (43% and 26%, respectively). Consequently, guideline‐based risk stratification may misclassify a significant proportion of patients, leading to inappropriate treatment decisions regarding novel MASLD therapies approved for F2/F3 fibrosis.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 291 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.